Home Sitemap Contact us Accessibility Statement Top of the page



Prescribing CINQAERO®

CINQAERO® (reslizumab) is an add-on therapy for the management of severe eosinophilic asthma.1

Available as:

  • CINQAERO® 10mg/mL concentrate for solution for infusion; it is licensed for adults aged 18 years and over.1

Therapeutic indications 

CINQAERO® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.1

Facts about CINQAERO®

  • The annual rate of asthma exacerbations was reduced by 54% in patients receiving reslizumab compared to placebo.2
  • Improvement in FEV1 was significantly greater in patients receiving reslizumab compared to placebo (0.22 vs 0.12 at Week 52; p<0.0001).2
  • Significantly reduced the rate of clinical asthma exacerbations*1,2
  • Significantly improved lung function (FEV1) from Week 4 through to Week 52*1,2
  • Significantly improved quality of life (AQLQ) from week 16 through to Week 52*1,2

*Data from two randomised, double-blind, placebo-controlled clinical trials (n=953) in a targeted patient population with inadequately controlled asthma and elevated blood eosinophils (≥400 cells/μL). Patients received either placebo (n=476) or CINQAERO® (n=477). Both treatments were added to standard of care.1,2

[Pooled analysis of two studies where patients with blood eosinophils ≥400 cells/µL and one or more exacerbations in the previous year were randomised to reslizumab 3mg/kg by i.v. infusion (n=477) or placebo (n=476) every four weeks.]


CINQAERO® is provided as a concentrate for solution for infusion, in a single-use vial.1

Reslizumab is a humanised monoclonal antibody that binds specifically to interleukin-5, a major cytokine responsible for the differentiation, maturation, recruitment and activation of eosinophils  - which have a role in inadequately controlled asthma.1,2

CINQAERO® targets IL-5 to reduce eosinophilic airway inflammation and reduce blood eosinophils.1,2

Marketing Authorisation

Teva Pharma B.V.
Swensweg 5,
2031GA Haarlem
The Netherlands

Marketing Authorisation number(s)

  • EU/1/16/1125/001
  • EU/1/16/1125/002

Resources for CINQAERO®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect

Medicine supporting documentation for CINQAERO®

1. CINQAERO® Summary of Product Characteristics. Teva Pharmaceuticals Europe B.V.

2. Castro M, Zangrilli J, Wechsler ME et al. Lancet Respir Med, 2015; 3: 355-66.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a